Company: Grey Wolf Therapeutics Ltd.
Job title: Chief Executive Officer & Co-founder
ERAP1 Inhibition to Generate Neoantigens & Drive Anti-Tumour Cell Killing 12:00 pm
Targeting the endoplasmic reticulum in the antigen presentation pathway to create novel neoantigens in cancer Increasing tumour visibility and extending the therapeutic benefit of immunotherapy to many more cancer patients Presenting Grey Wolf’s 1st in class ERAP1 inhibitor as a therapeutic pipeline for opportunitiesRead more
day: Day Two